Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Myriad caught in Prometheus line of fire; SCOTUS vacates/remands

This article was originally published in Scrip

Executive Summary

The Supreme Court in a 26 March grant-vacate-remand (GVR) order asked the US Court of Appeals for the Federal Circuit to take another look at its July 2011 ruling that Myriad Genetics' composition patent claims covering the BRCA1 and BRCA2 genes are valid and that the isolated DNA molecules do not exist in nature (scripintelligence.com, 1 August 2011, 4 April 2011, 5 April 2011).

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC016747

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel